Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer

Boston Scientific to acquire Penumbra in $14.5 billion deal

Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion

WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing

The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing

Vetter advances next-gen syringe closure system towards 2027 launch

The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats

Avantium and Packamama join forces to revolutionise wine packaging with plant-based polymer

The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles

Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology

EMA and FDA unveil joint AI principles to transform drug revelopment

Experts caution that realizing AI’s potential requires careful management and risk mitigation

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company